pubmed.ncbi.nlm.nih.gov

Pentoxifylline as an adjunctive in treatment of negative symptoms in chronic schizophrenia: A double-blind, randomized, placebo-controlled trial - PubMed

Randomized Controlled Trial

. 2023 Jan;29(1):354-364.

doi: 10.1111/cns.14010. Epub 2022 Nov 7.

Affiliations

Randomized Controlled Trial

Pentoxifylline as an adjunctive in treatment of negative symptoms in chronic schizophrenia: A double-blind, randomized, placebo-controlled trial

Mahmoud S Abdallah et al. CNS Neurosci Ther. 2023 Jan.

Retraction in

Abstract

Aim: The aim of this study was to explore the effectiveness and safety of pentoxifylline as an adjuvant to risperidone in mitigating the negative symptoms in patients with chronic schizophrenia.

Methods: In this randomized, placebo-controlled study, eighty outpatients with chronic schizophrenia were given risperidone for 8 weeks along with either pentoxifylline or a placebo. The positive and negative syndrome scale (PANSS) was used to assess patients at the start of the trial, as well as at 2, 4, 6, and 8 weeks. Pre- and posttreatment serum levels of cAMP, TNF-α-, and IL-6 were measured.

Results: The pentoxifylline group revealed a significant effect for time-treatment interaction on PANSS-negative subscale scores (p < 0.001), PANSS general psychopathology subscale scores (p < 0.001), and PANSS total scores (p < 0.001), but not on PANSS-positive subscale scores (p = 0.169). Additionally, when compared to the placebo group, the pentoxifylline group demonstrated a statistically significant increase in cAMP serum level and a statistically significant decrease in TNF-α and IL-6 serum levels.

Conclusion: Pentoxifylline adjunctive therapy with risperidone for 8 weeks was found to be promising in mitigating the negative symptoms in patients with chronic schizophrenia.

Trial registration number: NCT04094207.

Keywords: PANSS; inflammatory cytokines; negative symptoms; pentoxifylline; phosphodiesterase inhibitor; schizophrenia.

© 2022 The Authors. CNS Neuroscience & Therapeutics published by John Wiley & Sons Ltd.

PubMed Disclaimer

Conflict of interest statement

The authors state they have no competing or financial interests.

Figures

FIGURE 1
FIGURE 1

Flow chart of the study participants

FIGURE 2
FIGURE 2

The two therapies' effects on the Positive and Negative Syndrome Scale (PANSS). Data presented as means ± SD: (A) Negative, (B) Positive, (C) General psychopathology, and (D) Total scores. NS, non‐significant

Similar articles

References

    1. Kirkpatrick B, Fenton WS, Carpenter WT Jr, Marder SR. The NIMH‐MATRICS consensus statement on negative symptoms. Schizophr Bull. 2006;32(2):214‐219. - PMC - PubMed
    1. Möller HJ. Management of the negative symptoms of schizophrenia: new treatment options. CNS Drugs. 2003;17(11):793‐823. - PubMed
    1. Correll CU, Schooler NR. Negative symptoms in schizophrenia: a review and clinical guide for recognition, assessment, and treatment. Neuropsychiatr Dis Treat. 2020;16:519‐534. - PMC - PubMed
    1. Goldsmith DR, Rapaport MH. Inflammation and negative symptoms of schizophrenia: implications for reward processing and motivational deficits. Front Psychiatry. 2020;11:46. - PMC - PubMed
    1. Cerveri G, Gesi C, Mencacci C. Pharmacological treatment of negative symptoms in schizophrenia: update and proposal of a clinical algorithm. Neuropsychiatry Dis Treat. 2019;15:1525‐1535. - PMC - PubMed

Publication types

MeSH terms

Substances